Physician profile
Shannon E Wakeley
NPI 1942350905
$77,984.74
in general payments reported to CMS, 2019-2025
41 companies · $35.26 in 2025
The $35.26 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $3,274 · 2021: $416 · 2022: $1,218 · 2023: $1,352 · 2024: $328 · 2025: $35.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.12 |
| Education | $225.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35,761.08 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $7,231.56 | 2019-2024 | Jardiance, Mounjaro, Baqsimi |
| Novo Nordisk INC | $6,826.15 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $5,385.10 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,611.62 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $4,538.23 | 2019-2024 | |
| Abbvie INC. | $3,843.68 | 2019-2022 | |
| Medtronic Minimed, INC. | $3,017.27 | 2019-2020 | |
| Dexcom, INC. | $2,586.53 | 2019-2022 | |
| Valeritas, INC. | $1,796.24 | 2019 | |
| Ascensia Diabetes Care US INC. | $320.93 | 2019-2024 | |
| Abbott Laboratories | $214.94 | 2022-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $202.27 | 2019-2023 | Afrezza |
| Corcept Therapeutics | $184.00 | 2019-2023 | Korlym |
| Medtronic, INC. | $155.44 | 2021-2024 | Minimed 780g |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $149.89 | 2019-2022 | |
| Horizon Therapeutics Plc | $135.86 | 2020-2023 | Tepezza |
| Antares Pharma, INC. | $128.85 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Zealand Pharma US, INC. | $116.16 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $84.41 | 2019-2024 | Unithroid |
| Insulet Corporation | $67.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $65.47 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $57.04 | 2023-2024 | Signifor Lar, Isturisa |
| Amryt Pharma Holdings Ltd | $56.39 | 2022-2023 | Mycapssa |
| Amarin Pharma, INC. | $50.99 | 2019-2020 | |
| Beta Bionics, INC. | $49.25 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ipsen Biopharmaceuticals, INC | $45.85 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $39.62 | 2023-2024 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $36.89 | 2021-2023 | |
| Nevro Corp. | $35.07 | 2023 | Senza |
| Lifescan, INC. | $29.86 | 2019-2020 | |
| Astellas Pharma US INC | $27.80 | 2023 | Veozah |
| Esperion Therapeutics, INC. | $27.48 | 2020-2022 | |
| Eisai INC. | $19.65 | 2024 | |
| Halozyme INC | $18.79 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $16.69 | 2023 | Inpefa |
| Cequr Corporation | $14.65 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2021 | |
| Radius Health, INC. | $11.41 | 2019 | |
| Ibsa Pharma INC. | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Wakeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.